DYN - Dyne Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

518.7M

Cash

238.2M

Avg Qtr Burn

-37.45M

Short % of Float

11.88%

Insider Ownership

1.67%

Institutional Own.

97.51%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DYNE-251 Details Duchenne muscular dystrophy	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DYNE-101 Details Myotonic Dystrophy Type 1	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.